Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195296 | 0.81 | CA5A (0.39) | CA5ALMNACYP2A6RAB9AMAPT | |
| SCHEMBL1636309 | 0.81 | LMNA (0.46) | CA5ALMNACYP2A6RAB9AMAPT | |
| SCHEMBL5052149 | 0.79 | TPMT (0.56) | CA5ALMNAMAPTSMN1; SMN2HPGD | |
| SCHEMBL1971878 | 0.77 | PARP1 (0.45) | MAPTSMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL669554 | 0.76 | CA5A (0.67) | CA5ALMNACYP2A6RAB9AMAPT | |
| SCHEMBL6377610 | 0.74 | CA5A (0.50) | CA5ALMNACYP2A6RAB9AMAPT | |
| SCHEMBL2088791 | 0.74 | CA5A (0.50) | CA5ALMNACYP2A6RAB9AMAPT | |
| SCHEMBL1636120 | 0.74 | — | — | |
| SCHEMBL4200023 | 0.73 | CA1 (0.56) | LMNAMAPTHPGDL3MBTL1TDP1 | |
| SCHEMBL4187982 | 0.73 | ALDH1A1 (0.42) | LMNAMAPTSMN1; SMN2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324223-B2 | Substituted thieno [2,3-d] pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-8309735-B2 | Heterocyclic compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2012-11-13 | — | — | US | claimed |
| CN-101233135-B | Diaryl-purine, diaryl-azapurine and diaryl-deazapurine compounds as non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus | ARDEA BIOSCIENCES INC | 2012-10-03 | — | — | CN | claimed |
| US-20120225894-A1 | Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | claimed |
| EP-1877411-B9 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-08-29 | — | — | EP | claimed |
| US-8211898-B2 | Substituted thieno[3,2-d]pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-07-03 | — | — | US | claimed |
| EP-1877411-B1 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-01-18 | — | — | EP | claimed |
| EP-2132211-A2 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | Ardea Biosciences, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| US-20090281124-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-11-12 | — | — | US | claimed |
| US-7595324-B2 | Substituted thieno[3,2-D]pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2009-09-29 | — | — | US | claimed |
| EP-2024357-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jereni AG (DE) | 2009-02-18 | — | — | EP | claimed |
| EP-1877411-A4 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | claimed |
| CN-101233135-A | Diaryl-purine, diaryl-azapurine and diaryl-deazapurine compounds as non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus | ARDEA BIOSCIENCES INC (US) | 2008-07-30 | — | — | CN | claimed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | claimed |
| WO-2008058285-A2 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-1877411-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | Ardea Biosciences, Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2007131764-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-11-22 | — | — | WO | claimed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | claimed |
| WO-2006122003-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2006-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | CA5A 3003/4885LMNA 1193/4885CYP2A6 1080/4885 |
| US-20120225894-A1 | Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors | TYMS, DUT, TYMP | CA5A 4523/4885LMNA 2489/4885CYP2A6 832/4885 |
| US-20090281124-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | CA5A 3003/4885LMNA 1193/4885CYP2A6 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.